<div id="readability-page-1"><p>The Oncology Institute, Inc. (NASDAQ:TOI - Get Free Report) major shareholder Jorey Chernett purchased 30,000 shares of the firm's stock in a transaction on Tuesday, May 19th. The stock was bought at an average cost of $4.09 per share, with a total value of $122,700.00. Following the completion of the purchase, the insider owned 10,529,358 shares of the company's stock, valued at approximately $43,065,074.22. This represents a 0.29% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Major shareholders that own 10% or more of a company's shares are required to disclose their transactions with the SEC.</p><div><p><span></span><span>Get <strong>Oncology Institute</strong> alerts:</span></p></div><p>Jorey Chernett also recently made the following trade(s): </p><ul><li>On Thursday, April 9th, Jorey Chernett purchased 20,000 shares of Oncology Institute stock. The stock was bought at an average cost of $3.10 per share, with a total value of $62,000.00. </li><li>On Tuesday, March 24th, Jorey Chernett purchased 125,000 shares of Oncology Institute stock. The stock was bought at an average cost of $3.11 per share, with a total value of $388,750.00. </li><li>On Friday, March 20th, Jorey Chernett purchased 25,000 shares of Oncology Institute stock. The stock was bought at an average cost of $3.35 per share, with a total value of $83,750.00. </li><li>On Tuesday, March 17th, Jorey Chernett purchased 75,000 shares of Oncology Institute stock. The stock was bought at an average cost of $3.42 per share, with a total value of $256,500.00. </li><li>On Monday, March 16th, Jorey Chernett purchased 60,985 shares of Oncology Institute stock. The stock was bought at an average cost of $3.29 per share, with a total value of $200,640.65. </li><li>On Friday, March 13th, Jorey Chernett purchased 263,000 shares of Oncology Institute stock. The stock was bought at an average cost of $2.92 per share, with a total value of $767,960.00. </li></ul><h2>Oncology Institute Stock Up 0.9%</h2><p>TOI traded up $0.04 during midday trading on Wednesday, hitting $4.14. The company had a trading volume of 851,220 shares, compared to its average volume of 1,884,372. The company has a market capitalization of $408.70 million, a price-to-earnings ratio of -11.20 and a beta of 0.33. The stock's 50 day moving average price is $3.40 and its 200 day moving average price is $3.33. The Oncology Institute, Inc. has a 52 week low of $2.02 and a 52 week high of $4.88. </p><p>Oncology Institute (NASDAQ:TOI - Get Free Report) last posted its earnings results on Thursday, May 7th. The company reported ($0.02) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.05. The business had revenue of $147.44 million for the quarter, compared to the consensus estimate of $142.10 million.  Research analysts predict that  The Oncology Institute, Inc. will post -0.2 EPS for the current year. </p><h2>Institutional Investors Weigh In On Oncology Institute</h2><p>Large investors have recently modified their holdings of the stock. Josh Arnold Investment Consultant LLC lifted its stake in  Oncology Institute by 1,104.3% in the fourth quarter. Josh Arnold Investment Consultant LLC now owns 2,459,809 shares of the company's stock valued at $8,757,000 after purchasing an additional 2,255,559 shares during the last quarter.  CenterBook Partners LP lifted its position in shares of  Oncology Institute by 277.8% during the 3rd quarter. CenterBook Partners LP now owns 2,704,650 shares of the company's stock valued at $9,439,000 after buying an additional 1,988,751 shares during the last quarter.  Kanen Wealth Management LLC bought a new position in shares of  Oncology Institute during the 3rd quarter worth $6,421,000.  Marshall Wace LLP purchased a new stake in  Oncology Institute in the 2nd quarter worth about $3,028,000.  Finally, Geode Capital Management LLC increased its holdings in  Oncology Institute by 231.7% in the 2nd quarter. Geode Capital Management LLC now owns 1,279,443 shares of the company's stock worth $2,623,000 after acquiring an additional 893,696 shares during the last quarter. Hedge funds and other institutional investors own  36.86% of the company's stock. </p><h2>Analyst Upgrades and Downgrades</h2><p>Several equities research analysts have recently commented on the stock. Needham &amp; Company LLC  reissued a &#34;buy&#34; rating and set a $5.00 target price on shares of Oncology Institute in a research report on Monday, March 9th. BTIG Research  restated a &#34;buy&#34; rating and issued a $7.00 target price on shares of Oncology Institute in a research note on Monday, March 9th. B. Riley Financial upped their target price on Oncology Institute from $6.00 to $8.00 and gave the company a &#34;buy&#34; rating in a report on Friday, March 13th. Finally, Weiss Ratings  reiterated a &#34;sell (d-)&#34; rating on shares of Oncology Institute in a report on Monday, April 20th. Four investment analysts have rated the stock with a Buy rating and one  has issued  a Sell rating to the stock. Based on data from MarketBeat.com, Oncology Institute presently has an average rating of &#34;Moderate Buy&#34; and an average price target of $7.00.</p><p><b>Get Our Latest Report on TOI</b></p><h2>About Oncology Institute</h2> (Get Free Report)<p>The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials &amp; Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Oncology Institute</li><li>3 Space Infrastructure Stocks Gaining Momentum Ahead of the SpaceX IPO</li><li>The Great AI Rotation: Cashing In on Data</li><li>Mirum Pharma: A Rare Disease Growth Story to Watch</li><li>The Great Cloud Divide: How AI Is Reshuffling the Software Deck</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VE9J?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VE9J"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Oncology Institute Right Now?</h2><p>Before you consider Oncology Institute, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oncology Institute wasn't on the list.</p><p>While Oncology Institute currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

LABU

SBIO

<p>Oncology Institute major shareholder Jorey Chernett purchased 30,000 shares at $4.09 each, totaling $122,700, increasing his ownership to 10,529,358 shares. This transaction was disclosed to the SEC. Chernett has made several other purchases recently, totaling significant investments in the company. The stock is currently trading at $4.14, with a market cap of $408.70 million.</p>

Market Beat

Oncology Institute

First Trust NYSE Arca Biotech Index Fd

Direxion S&P Biotech Bull 3X

Proshares Ultra Nasdaq Biotech

Invesco Biotechnology & Genome ETF

VanEck Biotech ETF

iShares Biotechnology ETF

SPDR S&P Biotech

ALPS Medical Breakthrough

Oncology Institute - CW22

Insider Buying: Oncology Institute (NASDAQ:TOI) Major Shareholder Buys 30,000 Shares of Stock